Evaluation of viral load thresholds for predicting new World Health Organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy
- PMID: 22343177
- PMCID: PMC3360833
- DOI: 10.1097/QAI.0b013e31824e4da6
Evaluation of viral load thresholds for predicting new World Health Organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy
Abstract
Background: This study evaluated a wide range of viral load (VL) thresholds to identify a cut-point that best predicts new clinical events in children on stable highly active antiretroviral therapy (HAART).
Methods: Cox proportional hazards modeling was used to assess the adjusted risk for World Health Organization stage 3 or 4 clinical events (WHO events) as a function of time-varying CD4, VL, and hemoglobin values in a cohort study of Latin American children on HAART ≥6 months. Models were fit using different VL cut-points between 400 and 50,000 copies per milliliter, with model fit evaluated on the basis of the minimum Akaike information criterion value, a standard model fit statistic.
Results: Models were based on 67 subjects with WHO events out of 550 subjects on study. The VL cut-points of >2600 and >32,000 copies per milliliter corresponded to the lowest Akaike information criterion values and were associated with the highest hazard ratios (2.0, P = 0.015; and 2.1, P = 0.0058, respectively) for WHO events.
Conclusions: In HIV-infected Latin American children on stable HAART, 2 distinct VL thresholds (>2600 and >32,000 copies/mL) were identified for predicting children at significantly increased risk for HIV-related clinical illness, after accounting for CD4 level, hemoglobin level, and other significant factors.
Conflict of interest statement
Figures
Similar articles
-
Viral load predicts new world health organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy, independent of CD4 T lymphocyte value.Clin Infect Dis. 2010 Dec 1;51(11):1325-33. doi: 10.1086/657119. Epub 2010 Nov 1. Clin Infect Dis. 2010. PMID: 21039218 Free PMC article.
-
Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial.PLoS Med. 2017 Nov 14;14(11):e1002432. doi: 10.1371/journal.pmed.1002432. eCollection 2017 Nov. PLoS Med. 2017. PMID: 29136032 Free PMC article. Clinical Trial.
-
Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children.Pediatr Infect Dis J. 2004 Oct;23(10):923-30. doi: 10.1097/01.inf.0000142170.52155.7f. Pediatr Infect Dis J. 2004. PMID: 15602192 Clinical Trial.
-
Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old.Cochrane Database Syst Rev. 2013 Oct 10;10(10):CD010309. doi: 10.1002/14651858.CD010309.pub2. Cochrane Database Syst Rev. 2013. PMID: 24114324 Free PMC article. Review.
-
Point-of-care viral load tests to detect high HIV viral load in people living with HIV/AIDS attending health facilities.Cochrane Database Syst Rev. 2022 Mar 10;3(3):CD013208. doi: 10.1002/14651858.CD013208.pub2. Cochrane Database Syst Rev. 2022. PMID: 35266555 Free PMC article. Review.
Cited by
-
Correlates of High HIV Viral Load and Antiretroviral Therapy Adherence Among Viremic Youth in the United States Enrolled in an Adherence Improvement Intervention.AIDS Patient Care STDS. 2021 May;35(5):145-157. doi: 10.1089/apc.2021.0005. AIDS Patient Care STDS. 2021. PMID: 33960843 Free PMC article.
-
Frequent Episodes of Detectable Viremia in HIV Treatment-Experienced Children is Associated with a Decline in CD4+ T-cells Over Time.J AIDS Clin Res. 2016 Apr;7(4):565. doi: 10.4172/2155-6113.1000565. Epub 2016 Apr 14. J AIDS Clin Res. 2016. PMID: 27379199 Free PMC article.
References
-
- Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. [Accessed October 21, 2011];Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. 2011 Aug 11;:1–268. Available at http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf.
-
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; Oct 14, 2011. [Accessed October 21, 2011]. pp. 1–167. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
-
- Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med. 1997;336(19):1337–42. - PubMed
-
- Palumbo PE, Raskino C, Fiscus S, et al. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA. 1998;279(10):756–61. - PubMed
-
- Mofenson LM, Korelitz J, Meyer WA, 3rd, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and longterm mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. J Infect Dis. 1997;175(5):1029–38. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials